首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1746583

日本蛋白質治療市場報告（按產品（單株抗體、人類胰島素、促紅血球生成素、凝血因子、融合蛋白等）、治療領域、功能和地區分類）2025 年至 2033 年

Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本蛋白質療法市場規模達303億美元。展望未來， IMARC Group預計到2033年，市場規模將達到538億美元，2025-2033年期間的複合年成長率（CAGR）為6.27%。癌症、糖尿病和自體免疫疾病等慢性疾病發生率的上升，導致對蛋白質療法的需求增加，從而提供有針對性的、有效的治療，從而推動市場發展。

蛋白質療法是指利用蛋白質（通常是生物衍生的分子）來預防、控制或治療各種疾病和病症的一類醫療手段。這些治療性蛋白質包括抗體、酵素、荷爾蒙或其他在人體生物過程中發揮關鍵作用的功能性蛋白質。蛋白質療法旨在針對特定的疾病機制，例如與癌細胞結合或調節免疫反應，與傳統藥物相比，其精準度更高且副作用更少。它們通常採用包括重組DNA技術在內的生物技術生產，並可透過注射、輸注或其他給藥方式給藥。蛋白質療法的例子包括用於治療類風濕性關節炎等自體免疫疾病的單株抗體、用於治療糖尿病的胰島素以及用於治療血友病的凝血因子。這些療法徹底改變了醫學，為多種疾病提供了有效的治療方法，並透過持續的研發努力不斷取得進展。

日本蛋白質治療市場趨勢：

日本蛋白質療法市場蓬勃發展，得益於幾個關鍵促進因素。首先，生物技術的進步為蛋白質藥物的開發開闢了新的途徑。重組DNA技術的日益普及便是例證，該技術能夠生產出特異性和有效性更高的治療性蛋白質。此外，癌症、糖尿病和自體免疫疾病等慢性疾病的發生率不斷上升，也推動了對創新治療方案的需求。因此，製藥公司正在大力投資研發，以開發針對這些疾病的新型蛋白質療法。此外，日本人口老化也是蛋白質療法市場的重要驅動力。隨著老齡人口的成長，對能夠治療與年齡相關疾病的療法的需求也隨之增加，這進一步刺激了對蛋白質藥物的需求。此外，在預測期內，個人化醫療（根據個別患者客製化治療方案）的新興趨勢預計將推動日本蛋白質療法市場的發展。

日本蛋白質治療市場細分：

產品洞察：

單株抗體（mAb）
人類胰島素
促紅血球生成素
凝血因子
融合蛋白
其他

治療領域見解：

代謝紊亂
免疫疾病
血液系統疾病
癌症
荷爾蒙失調
遺傳性疾病
其他

功能洞察：

酶促和調節活性
特殊目標活動
疫苗
蛋白質診斷

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本蛋白質治療市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本蛋白質療法市場有何影響？
日本蛋白質治療市場依產品分類是怎樣的？
日本蛋白質治療市場依治療領域分類是怎麼樣的？
日本蛋白質治療市場根據功能如何分類？
日本蛋白質療法市場的價值鏈分為哪些階段？
日本蛋白質療法的主要促進因素和挑戰是什麼？
日本蛋白質治療市場的結構是怎麼樣的？主要參與者是誰？
日本蛋白質治療市場的競爭程度如何？

本報告回答的關鍵問題：

日本蛋白質治療市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本蛋白質療法市場有何影響？
日本蛋白質治療市場依產品分類是怎樣的？
日本蛋白質治療市場依治療領域分類是怎麼樣的？
日本蛋白質治療市場根據功能如何分類？
日本蛋白質療法市場的價值鏈分為哪些階段？
日本蛋白質療法的主要促進因素和挑戰是什麼？
日本蛋白質治療市場的結構是怎麼樣的？主要參與者是誰？
日本蛋白質治療市場的競爭程度如何？

Japan protein therapeutics market size reached USD 30.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 53.8 Billion by 2033, exhibiting a growth rate (CAGR) of 6.27% during 2025-2033. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.

Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.

Japan Protein Therapeutics Market Trends:

The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.

Japan Protein Therapeutics Market Segmentation:

Product Insights:

Monoclonal Antibodies (mAbs)
Human Insulin
Erythropoietin
Clotting Factors
Fusion Protein
Others

Therapy Area Insights:

Metabolic Disorders
Immunological Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others

Function Insights:

Enzymatic and Regulatory Activity
Special Targeting Activity
Vaccines
Protein Diagnostics

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan protein therapeutics market?
What is the breakup of the Japan protein therapeutics market on the basis of product?
What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
What is the breakup of the Japan protein therapeutics market on the basis of function?
What are the various stages in the value chain of the Japan protein therapeutics market?
What are the key driving factors and challenges in the Japan protein therapeutics?
What is the structure of the Japan protein therapeutics market and who are the key players?
What is the degree of competition in the Japan protein therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Protein Therapeutics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Protein Therapeutics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Protein Therapeutics Market - Breakup by Product

6.1 Monoclonal Antibodies (mAbs)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Human Insulin
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Erythropoietin
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Clotting Factors
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Fusion Protein
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Protein Therapeutics Market - Breakup by Therapy Area

7.1 Metabolic Disorders
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Immunological Disorders
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Hematological Disorders
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Cancer
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Hormonal Disorders
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Genetic Disorders
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Protein Therapeutics Market - Breakup by Function

8.1 Enzymatic and Regulatory Activity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Special Targeting Activity
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Vaccines
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Protein Diagnostics
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)

9 Japan Protein Therapeutics Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Protein Therapeutics Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis